Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 1/2013

01.02.2013 | Research Article

X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis

verfasst von: Fu-Ren Zeng, Yang Ling, Jie Yang, Xiao-Cai Tian, Xin Yang, Rong-Cheng Luo

Erschienen in: Tumor Biology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

X-ray repair cross-complementing group 1 (XRCC1), a DNA repair enzyme, plays a crucial role in the base excision repair by generating a single nucleotide repair patch. It has been demonstrated that the XRCC1 Arg399Gln gene polymorphism was associated with variations in XRCC1 enzyme activity. The aim of this study was to quantitatively summarize the association between the XRCC1 Arg399Gln polymorphism and susceptibility to colorectal cancer (CRC). A comprehensive search of the PubMed, Embase, and China National Knowledge Infrastructure databases was conducted for studies on the association between the XRCC1 Arg399Gln polymorphism and CRC risk. Summary odds ratio (OR) with its corresponding 95 % confidence interval (95 %CI) was estimated, in a fixed-effects model or a random-effects model when appropriate, to assess the association. Totally, 26 case–control studies with 6,979 cases and 11,470 controls were included into this meta-analysis. The pooled results of total studies showed that the XRCC1 Arg399Gln polymorphism was significantly associated with increased risk of CRC in all genetic contrast models (ORA vs. G = 1.13, 95 %CI 1.03–1.23, P OR = 0.008; ORGln/Gln vs. Arg/Arg = 1.24, 95 %CI 1.04–1.46, P OR = 0.015; ORGln/Gln vs. Arg/Gln + Arg/Arg = 1.19, 95 %CI 1.03–1.38, P OR = 0.021; ORGln/Gln + Arg/Gln vs. Arg/Arg = 1.14, 95 %CI 1.02–1.28, P OR = 0.022), except for the additive contrast model (ORArg/Gln vs. Arg/Arg = 1.11, 95 %CI 0.99–1.25, P OR = 0.064). The statistically significant association between the XRCC1 Arg399Gln polymorphism and CRC risk was observed among studies with high quality and in Asians, but not in Caucasians. Sensitivity analyses by sequential omission of any individual studies further identified the significant association. Publication bias was inexistent in this meta-analysis. The meta-analysis suggests that the XRCC1 Arg399Gln polymorphism is associated with increased risk of CRC.
Literatur
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Schee K, Flatmark K, Holm R, Boye K, Paus E. Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients. Tumour Biol. 2012;33:73–83.PubMedCrossRef
3.
Ueno H, Mochizuki H, Akagi Y, Kusumi T, Yamada K, Ikegami M, et al. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol. 2012;30:1519–26.PubMedCrossRef
4.
Ashktorab H, Schaffer AA, Daremipouran M, Smoot DT, Lee E, Brim H. Distinct genetic alterations in colorectal cancer. PLoS One. 2010;5:e8879.PubMedCrossRef
5.
Hirata H, Hinoda Y, Matsuyama H, Tanaka Y, Okayama N, Suehiro Y, et al. Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochem Biophys Res Commun. 2006;342:1058–62.PubMedCrossRef
6.
Mathiaux J, Le Morvan V, Pulido M, Jougon J, Begueret H, Robert J. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011;15:159–66.PubMedCrossRef
7.
Engin AB, Karahalil B, Karakaya AE, Engin A. Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population. Arh Hig Rada Toksikol. 2011;62:207–14.PubMedCrossRef
8.
Muniz-Mendoza R, Ayala-Madrigal ML, Partida-Perez M, Peregrina-Sandoval J, Leal-Ugarte E, Macias-Gomez N, et al. MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer. Genet Mol Res. 2012;11:2315–20.PubMedCrossRef
9.
Zhao Y, Deng X, Wang Z, Wang Q, Liu Y. Genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer in Chinese population. Asian Pac J Cancer Prev. 2012;13:665–9.PubMedCrossRef
10.
Yin G, Morita M, Ohnaka K, Toyomura K, Hamajima N, Mizoue T, et al. Genetic polymorphisms of XRCC1, alcohol consumption, and the risk of colorectal cancer in Japan. J Epidemiol. 2012;22:64–71.PubMedCrossRef
11.
Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–8.PubMedCrossRef
12.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
13.
Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed
14.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
15.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
16.
Md A, J W, A T, A C, R S. Facial artery and atherosclerosis. Folia Morphol (Warsz). 1999;58:199–206.
17.
Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 70–1.PubMedCrossRef
18.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
19.
Canbay E, Cakmakoglu B, Zeybek U, Sozen S, Cacina C, Gulluoglu M, et al. Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population. Curr Med Res Opin. 2011;27:1295–302.PubMedCrossRef
20.
Gil J, Ramsey D, Stembalska A, Karpinski P, Pesz KA, Laczmanska I, et al. The C/A polymorphism in intron 11 of the XPC gene plays a crucial role in the modulation of an individual’s susceptibility to sporadic colorectal cancer. Mol Biol Rep. 2012;39:527–34.PubMedCrossRef
21.
Gsur A, Bernhart K, Baierl A, Feik E, Fuhrlinger G, Hofer P, et al. No association of XRCC1 polymorphisms Arg194Trp and Arg399Gln with colorectal cancer risk. Cancer Epidemiol. 2011;35:e38–41.PubMedCrossRef
22.
Zhu C, Zhang Y, Bao Q, Xu YF, Qu LL, Tang ZP, et al. The study on the relationship between XRCC1 gene polymorphisms and the susceptibility of colorectal cancer. Chin J dig. 2011;31:450–4 [Article in Chinese].
23.
Brevik A, Joshi AD, Corral R, Onland-Moret NC, Siegmund KD, Le Marchand L, et al. Polymorphisms in base excision repair genes as colorectal cancer risk factors and modifiers of the effect of diets high in red meat. Cancer Epidemiol Biomarkers Prev. 2010;19:3167–73.PubMedCrossRef
24.
Jelonek K, Gdowicz-Klosok A, Pietrowska M, Borkowska M, Korfanty J, Rzeszowska-Wolny J, et al. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet. 2010;51:343–52.PubMedCrossRef
25.
Wang J, Zhao Y, Jiang J, Gajalakshmi V, Kuriki K, Nakamura S, et al. Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk: a case–control study in an Indian population. J Cancer Res Clin Oncol. 2010;136:1517–25.PubMedCrossRef
26.
Huang S, Yi B, Yang XH, Rui R, Miao XP. Polymorphisms of DNA repair gene XRCC1 and genetic susceptibility to colorectal cancer. Chin J Exp Surg. 2010;27:1057–9 [Article in Chinese].
27.
Curtin K, Samowitz WS, Wolff RK, Ulrich CM, Caan BJ, Potter JD, et al. Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:3384–8.PubMedCrossRef
28.
Improta G, Sgambato A, Bianchino G, Zupa A, Grieco V, La Torre G, et al. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case–control study in a Southern Italian population. Anticancer Res. 2008;28:2941–6.PubMed
29.
Sliwinski T, Krupa R, Wisniewska-Jarosinska M, Lech J, Morawiec Z, Chojnacki J, et al. No association between the Arg194Trp and Arg399Gln polymorphisms of the XRCC1 gene and colorectal cancer risk and progression in a Polish population. Exp Oncol. 2008;30:253–4.PubMed
30.
Song HN, Liu XL, Er YX, Li CH, Hou RP, Xu CQ, et al. The correlative study of the XRCC1 gene haplotype and risk of colorectal cancer in China. J Qiqihar Medi Colle. 2008; 29:2957–60. [Article in Chinese]
31.
Jin MJ, Chen K, Zhang Y, Zhang W, Liu B. Zhang YJ [Correlations of single nucleotide polymorphisms of DNA repair gene XRCC1 to risk of colorectal cancer]. Ai Zheng. 2007;26:274–9.PubMed
32.
Stern MC, Conti DV, Siegmund KD, Corral R, Yuan JM, Koh WP, et al. DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. Cancer Epidemiol Biomark Prev. 2007;16:2363–72.CrossRef
33.
Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. J Biomed Sci. 2007;14:183–93.PubMedCrossRef
34.
Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, Moran T, Cirauqui B, Catot S, et al. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep. 2007;17:637–45.PubMed
35.
Ren Z, Fan JW, Zhou CZ, Qiu GQ, He L, Peng ZH. Association between XRCC1 SNP and susceptibility to sporadic colorectal carcinoma. Chin J Exp Surg. 2007;24:1087–9 [Article in Chinese].
36.
Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006;12:2101–8.PubMedCrossRef
37.
Skjelbred CF, Saebo M, Wallin H, Nexo BA, Hagen PC, Lothe IM, et al. Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. BMC Cancer. 2006;6:67.PubMedCrossRef
38.
Hong YC, Lee KH, Kim WC, Choi SK, Woo ZH, Shin SK, et al. Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Int J Cancer. 2005;116:428–32.PubMedCrossRef
39.
Krupa R, Blasiak J. An association of polymorphism of DNA repair genes XRCC1 and XRCC3 with colorectal cancer. J Exp Clin Cancer Res. 2004;23:285–94.PubMed
40.
Abdel-Rahman SZ, Soliman AS, Bondy ML, Omar S, El-Badawy SA, Khaled HM, et al. Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer Lett. 2000;159:79–86.PubMedCrossRef
41.
Yu MW, Yang SY, Pan IJ, Lin CL, Liu CJ, Liaw YF, et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2003;95:1485–8.PubMedCrossRef
42.
Wang B, Wang D, Huang G, Zhang C, Xu DH, Zhou W. XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2010;25:313–21.PubMedCrossRef
Metadaten
Titel
X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis
verfasst von
Fu-Ren Zeng
Yang Ling
Jie Yang
Xiao-Cai Tian
Xin Yang
Rong-Cheng Luo
Publikationsdatum
01.02.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0581-2

Weitere Artikel der Ausgabe 1/2013

Tumor Biology 1/2013 Zur Ausgabe

Research Article

Expression of TWIST1, Snail, Slug, and NF-κB and methylation of the TWIST1 promoter in mammary phyllodes tumor

Research Article

Polymorphisms of DNA repair gene XRCC1 and hepatocellular carcinoma risk among East Asians: a meta-analysis

Research Article

The interaction between smoking and GSTM1 variant on lung cancer in the Chinese population

Research Article

Berberine inhibits the migration and invasion of T24 bladder cancer cells via reducing the expression of heparanase

Research Article

2-Deoxy-d-glucose and ferulic acid modulates radiation response signaling in non-small cell lung cancer cells

Research Article

Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise